0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T16:35:00Z
EKF Diagnostics Holdings Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
Mon 24 Apr 23, 05:01 AMA Look At The Fair Value Of EKF Diagnostics Holdings plc (LON:EKF)
Wed 29 Mar 23, 07:10 AMWhat Is EKF Diagnostics Holdings plc's (LON:EKF) Share Price Doing?
Wed 18 Jan 23, 12:09 PMShould You Investigate EKF Diagnostics Holdings plc (LON:EKF) At UK£0.38?
Thu 11 Aug 22, 08:35 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -8.94200M | 21.43M | 15.36M | 5.52M | 12.16M |
| Minority interest | -0.52500M | -0.30700M | 0.55M | 0.60M | 0.38M |
| Net income | -9.57600M | 15.85M | 11.11M | 3.68M | 10.11M |
| Selling general administrative | 23.18M | 17.71M | 20.66M | 18.28M | 10.59M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 24.04M | 39.37M | 37.42M | 23.73M | 22.70M |
| Reconciled depreciation | 6.66M | 5.88M | 4.61M | 4.44M | 3.99M |
| Ebit | 1.91M | 21.75M | 16.89M | 5.78M | 12.01M |
| Ebitda | 8.57M | 27.68M | 21.56M | 10.30M | 16.00M |
| Depreciation and amortization | 6.66M | 5.93M | 4.66M | 4.51M | 3.99M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1.91M | 21.75M | 16.89M | 5.78M | 12.20M |
| Other operating expenses | 64.86M | 60.09M | 48.37M | 39.13M | 30.34M |
| Interest expense | 0.10M | 0.36M | 1.59M | 0.34M | 0.04M |
| Tax provision | 0.63M | 5.28M | 3.97M | 1.59M | 1.87M |
| Interest income | 0.13M | 0.04M | 0.05M | 0.07M | 0.04M |
| Net interest income | 0.03M | -0.31200M | -1.53900M | 0.01M | 0.00800M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.63M | 5.28M | 3.97M | 1.59M | 1.87M |
| Total revenue | 66.64M | 81.84M | 65.26M | 44.92M | 42.54M |
| Total operating expenses | 22.26M | 17.62M | 20.52M | 17.94M | 10.50M |
| Cost of revenue | 42.60M | 42.47M | 27.84M | 21.19M | 19.85M |
| Total other income expense net | -10.85300M | -0.31200M | -1.53900M | -0.26600M | -0.03400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -9.57600M | 16.16M | 11.38M | 3.93M | 10.30M |
| Net income applicable to common shares | -10.10100M | 15.85M | 11.11M | 3.68M | 10.11M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 89.29M | 115.12M | 101.27M | 87.13M | 81.38M |
| Intangible assets | 8.65M | 14.51M | 12.65M | 13.95M | 16.86M |
| Earning assets | - | - | - | - | - |
| Other current assets | -0.01000M | 13.98M | -0.37100M | 8.10M | 7.43M |
| Total liab | 14.77M | 20.38M | 23.07M | 15.95M | 17.48M |
| Total stockholder equity | 73.35M | 94.12M | 77.65M | 70.57M | 63.53M |
| Deferred long term liab | 3.96M | 3.44M | 3.11M | 2.72M | 2.83M |
| Other current liab | 2.44M | 0.47M | 2.90M | 1.39M | 9.97M |
| Common stock | 4.55M | 4.64M | 4.55M | 4.54M | 4.54M |
| Capital stock | 4.55M | 4.64M | 4.55M | 4.54M | 4.54M |
| Retained earnings | 52.46M | 74.26M | 63.52M | 56.20M | 52.54M |
| Other liab | 2.49M | 5.20M | 2.64M | 2.62M | 3.18M |
| Good will | 25.12M | 27.38M | 24.40M | 23.82M | 24.91M |
| Other assets | 4.88M | 0.01M | 3.12M | 2.75M | 2.86M |
| Cash | 11.58M | 20.34M | 21.91M | 12.07M | 10.28M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11.74M | 13.65M | 19.42M | 12.86M | 13.60M |
| Current deferred revenue | - | 3.00M | 1.51M | 2.82M | - |
| Net debt | -10.03100M | -17.71200M | -20.33500M | -10.41700M | -9.40200M |
| Short term debt | 1.01M | 1.10M | 0.56M | 1.18M | 0.18M |
| Short long term debt | 0.14M | 0.27M | 0.18M | 0.17M | 0.18M |
| Short long term debt total | 1.55M | 2.63M | 1.58M | 1.66M | 0.88M |
| Other stockholder equity | 16.34M | 15.22M | 9.58M | 9.83M | 16.30M |
| Property plant equipment | 21.71M | 17.87M | 13.64M | 13.18M | 12.47M |
| Total current assets | 31.76M | 47.55M | 43.95M | 26.24M | 23.83M |
| Long term investments | - | - | - | - | 3.27M |
| Net tangible assets | 43.53M | 52.23M | 43.71M | 35.52M | 24.58M |
| Short term investments | - | - | - | - | - |
| Net receivables | 10.76M | 13.98M | 13.92M | 7.62M | 7.14M |
| Long term debt | 0.00000M | 0.43M | 0.32M | 0.48M | 0.69M |
| Inventory | 9.43M | 13.24M | 8.49M | 6.07M | 6.12M |
| Accounts payable | 8.29M | 9.08M | 14.44M | 7.47M | 1.23M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -12.30500M | -10.20000M | -9.84300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 4.55M | 4.54M | 4.54M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.12M | 7.79M | 6.61M | 9.90M | 3.27M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 57.53M | 67.56M | 57.31M | 60.88M | 57.55M |
| Capital lease obligations | 1.41M | 1.93M | 1.07M | 1.00M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -8.93200M | -5.47700M | 3.86M | -0.12400M | -3.11900M |
| Change to liabilities | -2.17700M | 1.22M | 1.89M | -5.47900M | -0.27100M |
| Total cashflows from investing activities | -8.93200M | -5.47700M | 1.34M | -2.39600M | -4.92800M |
| Net borrowings | -1.68400M | -0.82100M | -0.65200M | -0.56100M | -0.24200M |
| Total cash from financing activities | -11.03900M | -6.15500M | -5.20900M | -0.63400M | -1.49100M |
| Change to operating activities | - | - | - | - | - |
| Net income | -8.94200M | 21.43M | 15.36M | 5.52M | 10.11M |
| Change in cash | -8.76300M | -1.57200M | 9.84M | 1.79M | 2.08M |
| Begin period cash flow | 20.34M | 21.91M | 12.07M | 10.28M | 8.20M |
| End period cash flow | 11.58M | 20.34M | 21.91M | 12.07M | 10.28M |
| Total cash from operating activities | 9.69M | 10.24M | 13.81M | 5.10M | 8.32M |
| Issuance of capital stock | - | 0.00000M | 0.20M | 0.01M | 0.00000M |
| Depreciation | 6.66M | 5.88M | 4.61M | 4.44M | 3.99M |
| Other cashflows from investing activities | - | 0.04M | 0.05M | 0.07M | 0.04M |
| Dividends paid | 5.46M | 5.10M | 4.55M | 4.55M | 4.55M |
| Change to inventory | -0.81500M | -4.60100M | -2.55700M | 0.04M | -0.46100M |
| Change to account receivables | 1.28M | -3.27400M | -3.42600M | -0.32700M | 0.01M |
| Sale purchase of stock | -3.89600M | - | -0.00700M | -0.01500M | -0.94000M |
| Other cashflows from financing activities | -1.07100M | -0.87400M | -0.67800M | -0.43900M | -0.30900M |
| Change to netincome | 14.85M | -4.84000M | 2.18M | 2.75M | -5.05700M |
| Capital expenditures | 5.83M | 5.65M | 2.65M | 2.38M | 1.85M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -1.71600M | -6.65800M | -4.09500M | -5.76900M | -0.72100M |
| Stock based compensation | -0.30800M | -6.58600M | 4.78M | 2.12M | 0.94M |
| Other non cash items | 14.00M | 0.03M | 0.12M | -0.10100M | -5.99600M |
| Free cash flow | 3.86M | 4.59M | 11.16M | 2.73M | 6.47M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EKF EKF Diagnostics Holdings Plc |
-1.1 4.38% | 24.00 | - | - | 2.40 | 2.09 | 2.25 | -19.3996 |
| SN Smith & Nephew PLC |
-3.4 0.35% | 977.20 | 53.70 | 14.27 | 1.75 | 2.26 | 2.21 | 13.21 |
| MXCT MaxCyte Inc |
-23.0 6.65% | 323.00 | - | - | 10.41 | 2.15 | 6.75 | -6.5763 |
| NIOX NIOX Group PLC |
1.00 1.61% | 63.00 | 32.00 | 20.75 | 7.92 | 3.40 | 7.31 | 28.40 |
| CREO Creo Medical Group PLC |
0.75 4.62% | 17.00 | - | - | 4.53 | 1.91 | 3.91 | -4.68 |
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Avon House, Cardiff, United Kingdom, CF64 2EZ
| Name | Title | Year Born |
|---|---|---|
| Mr. David Michael Salter | CEO & Exec. Director | 1961 |
| Mr. Marc Peter Davies | CFO & Director | 1980 |
| Mr. Andrew Webb | Chief Exec. Officer of Ekf Molecular | NA |
| Mr. Salim Hamir F.C.A. | Company Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...